RESUMEN
Preoperative activity of arginase was determined in blood serum of 86 patients with colorectal liver metastases and compared with the level of CEA and Ca 19-9. Arginase activity was elevated in 94% patients, whereas the levels of CEA and CA 19-9 were higher in 63% and 45% patients, respectively. The number of not detected by each marker cases (false negative) was much lower in arginase determination (only 6%) than in CEA (37s%), and Ca 19-9 (55%). Sensitivity and specificity of arginase test was much higher than these of CEA and Ca 19-9. The combination of CEA or Ca 19-9 with arginase determination improved the sensitivity of either test, but the combined parameters were still lower than these for arginase itself. Obtained results indicate that arginase test demonstrate higher clinical value in the early diagnosis of colorectal liver metastases than CEA and Ca 19-9.
Asunto(s)
Arginasa/sangre , Biomarcadores de Tumor/sangre , Antígeno CA-19-9/sangre , Antígeno Carcinoembrionario/sangre , Neoplasias Colorrectales/patología , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/secundario , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Neoplasias Hepáticas/enzimología , Neoplasias Hepáticas/inmunología , Masculino , Persona de Mediana Edad , Sensibilidad y EspecificidadRESUMEN
Two microsatellite tandem repeated tetramers, (GACA)(4) and (CAAT)(4), were used for Proteus mirabilis strain differentiation. The microsatellite-based PCR tests were applied for the examination of interstrain diversity for 87 P. mirabilis strains. Forty-six of the investigated strains were clinical isolates (5 were hospital isolates and 39 were outpatient clinic isolates); 42 strains were derived from the Kauffmann-Perch collection of laboratory strains. Fingerprinting done with the tetramers had a high discrimination ability [0.992 and 0.940 for (GACA)(4) and (CAAT)(4), respectively]. The distributions of clinical isolates among well-defined laboratory strains, determined by numerical analysis (unweighted pair-group method with arithmetic averages; Dice similarity coefficient), proved their genetic similarity to reference strains in the Kauffmann-Perch collection. This analysis also indicated that it is possible to estimate some phenotypic properties of P. mirabilis clinical isolates solely on the basis of microsatellite fingerprinting.
Asunto(s)
Dermatoglifia del ADN/métodos , Repeticiones de Microsatélite/genética , Reacción en Cadena de la Polimerasa/métodos , Infecciones por Proteus/microbiología , Proteus mirabilis/clasificación , Técnicas de Tipificación Bacteriana , Humanos , Proteus mirabilis/genética , Reproducibilidad de los Resultados , Especificidad de la EspecieRESUMEN
The mean arginase activity in breast cancers (n = 80) was significantly higher than in control tissues and it accounted for 0.31 +/- 0.23 U/g wet tissue and 0.083 +/- 0.061 U/g (P < 0.05), respectively. With the cutoff value of 0.1 U/g wet tissue, raised arginase activity was observed in 74% of tumors. The preoperative arginase activity in blood serum from women with breast cancer was 11.2 +/- 7.9 U/l (n = 115), and it was significantly higher than in 70 healthy controls, where it was 5.7 +/- 2.4 U/l (P < 0.05). With the cutoff value for normal serum arginase activity above 8.0 U/l, the activity was raised in 10% of control individuals, and in 63% of women with breast cancer. The sensitivity and specificity of the arginase test in blood serum were 63% and 60%, respectively. Two isoforms immunologically identical to human kidney arginases (L-arginine amidinohydrolase) were found in both normal and cancerous breast tissues. The level of anionic form was similar in control and cancerous tissues, whereas the cationic isoform predominated in breast cancer. The cationic isoform was the only one present in serum of both ill and healthy women, and its level was higher in patients with breast cancer. Thus, it can be concluded that the cationic isoform is responsible for the increase of arginase activity in serum of patients with breast cancer.
Asunto(s)
Arginasa/sangre , Neoplasias de la Mama/enzimología , Adulto , Anciano , Femenino , Humanos , Isoenzimas/sangre , Persona de Mediana EdadRESUMEN
BACKGROUND: Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied. METHODS: Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years. RESULTS: Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut-off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died. CONCLUSIONS: The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM.
Asunto(s)
Adenocarcinoma/enzimología , Arginasa/sangre , Biomarcadores de Tumor/sangre , Neoplasias Colorrectales/enzimología , Neoplasias Hepáticas/enzimología , Recurrencia Local de Neoplasia/enzimología , Adenocarcinoma/secundario , Adenocarcinoma/cirugía , Adulto , Anciano , Neoplasias Colorrectales/patología , Neoplasias Colorrectales/cirugía , Femenino , Humanos , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/secundario , Recurrencia Local de Neoplasia/cirugía , Cuidados Posoperatorios , Cuidados Preoperatorios , PronósticoRESUMEN
Arginase activity in blood serum of 40 patients with primary colorectal cancer determined one day before tumour resection, was almost 5-times higher than that in serum of healthy blood donors. Preoperative increase of arginase activity was observed in 28 out of 40 patients (70%). Six days after tumour resection, arginase activity decreased to the normal value in most studied patients. In 32 patients (86%), the activity remained low during three years of surveillance, and no symptoms of carcinogenesis were observed. However, the postoperative raise of arginase activity was demonstrated in 5 patients--in 3 of them colorectal cancer recurred and 2 developed liver metastases. The increase of arginase activity in blood serum, after resection of primary colorectal cancer, may indicate tumour recurrence or liver metastases. Therefore, monitoring of postoperative arginase activity in patient's serum may be of diagnostic value.
Asunto(s)
Arginasa/sangre , Biomarcadores de Tumor/sangre , Neoplasias Colorrectales/enzimología , Neoplasias Hepáticas/enzimología , Recurrencia Local de Neoplasia/enzimología , Adulto , Anciano , Estudios de Casos y Controles , Neoplasias Colorrectales/patología , Neoplasias Colorrectales/cirugía , Femenino , Humanos , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/cirugía , Cuidados Posoperatorios , Análisis de Supervivencia , Factores de TiempoRESUMEN
Preoperative activity of arginase in blood serum of patients with colorectal cancer metastases to the liver is much higher than in serum of healthy blood donors. Before tumour resection in serum of 100 patients two cut-off levels of arginase activity were observed--in 65 subjects the activity ranged from 10 to 70 U/(group I), and in 35 subjects (group II), from 100 to 200 U/l. The raised arginase activity was observed in 83% of patients from group I, and in all studied patients (100%) from subgroup II. After liver surgery, arginase activity decreased to the normal value in the majority of patients. During three years of surveillance, in 88% and 63% of patients from either subgroup, respectively, no significant increase in arginase activity was observed, and the patients remained cancer-free. However, the rise of arginase activity was demonstrated in 13% and 37% subjects from either subgroup, respectively--the patients developed second liver metastases or died. Metastases and deaths were observed more often in patients from group II than I. The rise in arginase activity in blood serum after resection of colorectal cancer metastases to the liver indicates the possibility of new cancerogenesis. The special group at risk are patients with high (100 or more U/l) preoperative serum arginase activity.